This document is page 27 of a Cowen Collaborative Insights financial report dated February 25, 2019. The content is a market analysis of the CBD (Cannabidiol) industry, breaking down price per milligram across various product categories such as tinctures, gummies, and beauty products. While the content itself is strictly financial research regarding consumer staples, the document bears the Bates stamp 'HOUSE_OVERSIGHT_024843', indicating it was part of a document production for a US House Oversight Committee investigation.
| Name | Role | Context |
|---|---|---|
| Michael Cella | Recipient/Employee |
Named in the sidebar watermark: 'This report is intended for michael.cella@cowen.com'
|
| Name | Type | Context |
|---|---|---|
| Cowen |
Header and footer branding (Cowen Collaborative Insights, Cowen and Company).
|
|
| House Oversight Committee |
Implied by the Bates stamp 'HOUSE_OVERSIGHT_024843' at the bottom right.
|
| Location | Context |
|---|---|
|
Mentioned in point iii regarding the research on the CBD opportunity.
|
"Beauty Products Carry the Most Premium Pricing, While Tinctures and Gummies Offer the Best Value Proposition in Terms of Price / MG of CBD"Source
"To analyze the category's potential, we focused on six specific consumer product categories"Source
"Forecast run rate revenues by vertical over the next two years"Source
Complete text extracted from the document (2,192 characters)
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document